Trial reportNutrients2018
Galacto-Oligosaccharide/Polidextrose Enriched Formula Protects against Respiratory Infections in Infants at High Risk of Atopy: A Randomized Clinical Trial.
Trial report in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02116452 (Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy), which is not on this map. Cited by 32 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy
Who cites it
32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Effects of Infant Formula Supplemented With Prebiotics on the Gut Microbiome, Gut Environment, Growth Parameters, and Safety and Tolerance: A Systematic Review and Meta-Analysis.Nutrition reviews · 2025Pooled it
- Effects of probiotics, prebiotics, synbiotics and postbiotics on pediatric asthma: a systematic review.Frontiers in nutrition · 2025Pooled it
- The Effects of Prebiotics, Synbiotics, and Short-Chain Fatty Acids on Respiratory Tract Infections and Immune Function: A Systematic Review and Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- Modulation of gut microbiota protects against viral respiratory tract infections: a systematic review of animal and clinical studies.European journal of nutrition · 2021Pooled it
- Probiotics and Prebiotics Intervention in Respiratory and Digestive Infections Linked to Covid-19.Probiotics and antimicrobial proteins · 2025Review
- Involvement of Pruritus, Gut Dysbiosis and Histamine-Producing Bacteria in Paraneoplastic Syndromes.Biomedicines · 2025Article
- In Vivo Evidence on the Emerging Potential of Non-Digestible Oligosaccharides as Therapeutic Agents in Bacterial and Viral Infections.Nutrients · 2025Review
- Philippine guidelines on the dietary primary prevention of allergic diseases in children.Asia Pacific allergy · 2024Review
- Role of Human Milk Microbiota in Infant Neurodevelopment: Mechanisms and Clinical Implications.Children (Basel, Switzerland) · 2024Review
- Vitamin D and prebiotics for intestinal health in cystic fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 x 2 trial of administration of prebiotics and cholecalciferol (vitamin DContemporary clinical trials communications · 2024Article
- Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis: Rationale and design for a randomized, placebo-controlled, double-blind, 2 × 2 trial of administration of prebiotics and cholecalciferol (vitamin DmedRxiv : the preprint server for health sciences · 2024Article
- The Gut-Organ Axis within the Human Body: Gut Dysbiosis and the Role of Prebiotics.Life (Basel, Switzerland) · 2023Review
- Prebiotics in New-Born and Children's Health.Microorganisms · 2023Review
- The Link between Different Types of Prebiotics in Infant Formula and Infection Rates: A Review.Nutrients · 2023Review
- Pre-, pro-, syn-, and Postbiotics in Infant Formulas: What Are the Immune Benefits for Infants?Nutrients · 2023Review
- The lung-gut crosstalk in respiratory and inflammatory bowel disease.Frontiers in cellular and infection microbiology · 2023Review
- Gut Microbiota Dynamics in Relation to Long-COVID-19 Syndrome: Role of Probiotics to Combat Psychiatric Complications.Metabolites · 2022Review
- Manipulating Microbiota to Treat Atopic Dermatitis: Functions and Therapies.Pathogens (Basel, Switzerland) · 2022Review
- Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components: the PRIMA birth cohort.BMC infectious diseases · 2022Observational
- S3 guideline Allergy Prevention.Allergologie select · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly nutrition affects the risk of atopy and infections through modifications of intestinal microbiota. The Prebiotics in the Prevention of Atopy (PIPA) study was a 24-month randomised, double-blind, placebo-controlled trial. It aimed to evaluate the effects of a galacto-oligosaccharide/polydextrose (GOS/PDX)-formula (PF) on atopic dermatitis (AD) and common infections in infants who were born to atopic parents and to investigate the relationship among early nutrition, gut microbiota and clinical outcomes.
methodsA total of 201 and 199 infants were randomized to receive a PF and standard formula (SF), respectively; 140 infants remained on exclusive breastfeeding (BF).
resultsThe cumulative incidence of AD and its intensity and duration were not statistically different among the three groups. The number of infants with at least one episode of respiratory infection (RI) and the mean number of episodes until 48 weeks of age were significantly lower in the PF group than in the SF group. The number of patients with recurrent RIs and incidence of wheezing lower RIs until 96 weeks were lower in the PF group than the SF group, but similar to the BF group. Bifidobacteria and Clostridium cluster I colonization increased over time in the PF group but decreased in the SF and BF groups. Bifidobacteria had a protective role in RIs, whereas Clostridium cluster I was associated with atopy protection.
conclusionThe early administration of PF protects against RIs and mediates a species-specific modulation of the intestinal microbiota.
trial registrationclinicaltrial.gov Identifier: NCT02116452.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.